Nanoparticle-based compositions

• US 10,485,861 B2
• Filed: 03/14/2014
• Issued: 11/26/2019
• Est. Priority Date: 03/14/2013
• Status: Active Grant

• Current Assignee: Brigham and Women's Hospital Incorporated, President and Fellows of Harvard College (Harvard Corporation), Massachusetts Institute of Technology
• Original Assignee: President and Fellows of Harvard College (Harvard Corporation)
• Inventors: Stary, Georg, Radovic-Moreno, Aleksandar Filip, Basto, Pamela A., Starnbach, Michael N., Langer, Robert S., Farokhzad, Omid C., Andrian, Ulrich Von
• Primary Examiner(s): Hines, Jana A
• Application Number:
  US14/772,695
• Publication Number:
  US 20160008451A1
• Time in Patent Office: 2,083 Days
• CPC Class Codes: A61K 2039/521 inactivated (killed)
• CPC Class Codes: A61K 2039/5252 inactivated (killed)
• CPC Class Codes: A61K 2039/543 intranasal
• CPC Class Codes: A61K 2039/55555 Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
• CPC Class Codes: A61K 2039/55572 Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/4745 condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48
• CPC Class Codes: A61K 31/711 Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
• CPC Class Codes: A61K 39/0208 Specific bacteria not otherwise provided for
• CPC Class Codes: A61K 39/04 Mycobacterium, e.g. Mycobacterium tuberculosis
• CPC Class Codes: A61K 39/085 Staphylococcus
• CPC Class Codes: A61K 39/092 Streptococcus
• CPC Class Codes: A61K 39/118 Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/10 Antimycotics
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/14 for RNA viruses
• CPC Class Codes: A61P 31/16 for influenza or rhinoviruses
• CPC Class Codes: A61P 31/18 : for HIV
• CPC Class Codes: A61P 33/00 : Antiparasitic agents
• CPC Class Codes: A61P 37/04 : Immunostimulants
• CPC Class Codes: C12N 2740/16034 : Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: C12N 2760/16134 : Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: C12N 2760/18534 : Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: C12N 2770/16034 : Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: C12N 2770/20034 : Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: Y02A 50/30 : Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Provided herein are new compositions including an inactivated pathogen and one or more adjuvant-loaded polymeric nanoparticles, wherein the adjuvant-loaded nanoparticles are bound to the inactivated pathogen. These compositions are useful for preventing and/or treating diseases caused by the specific pathogens, especially when administered to a subject'"'"'s mucosal membranes.

Claims

1. A method of stimulating a resident mucosal memory T cell immune response against Chlamydia trachomatis in a subject in need thereof, the method comprising administering to the subject through a mucosal route an effective amount of a composition comprising a negatively charged inactivated Chlamydia trachomatis, and one or more adjuvant-loaded polymeric nanoparticles having a positive charge, wherein the one or more adjuvant-loaded polymeric nanoparticles are each attached to the inactivated Chlamydia trachomatis through electrostatic attraction, and the one or more adjuvant-loaded nanoparticles comprise poly(lactic-co-glycolic acid)-block-poly(L-histidine)-block-poly(ethylene glycol) (PLGA-PLH-PEG) triblock copolymers, thereby stimulating a resident mucosal memory T cell immune response against Chlamydia trachomatis in the subject.

2. The method of claim 1, wherein the one or more adjuvant-loaded polymeric nanoparticles comprise an adjuvant that targets an endosomal membrane.

3. The method of claim 1, wherein the one or more adjuvant-loaded polymeric nanoparticles comprise a Toll-like receptor agonist.

4. The method of claim 1, wherein the one or more adjuvant-loaded polymeric nanoparticles comprise biodegradable polymers.

5. The method of claim 1, wherein the one or more adjuvant-loaded polymeric nanoparticles comprise R848-polylactic acid.

6. The method of claim 1, wherein the composition is administered to the subject by an intranasal route.

7. The method of claim 1, wherein the composition is administered to the subject by an intrauterine route.